> top > docs > PubMed:17965424 > annotations

PubMed:17965424 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-189 Sentence denotes Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
T2 190-200 Sentence denotes OBJECTIVE:
T3 201-377 Sentence denotes A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
T4 378-399 Sentence denotes PATIENTS AND METHODS:
T5 400-569 Sentence denotes A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
T6 570-634 Sentence denotes Use of gastroprotective agents and low-dose aspirin was allowed.
T7 635-791 Sentence denotes The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
T8 792-885 Sentence denotes General safety was also assessed, including adjudicated thrombotic cardiovascular event data.
T9 886-988 Sentence denotes Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
T10 989-997 Sentence denotes RESULTS:
T11 998-1144 Sentence denotes Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.
T12 1145-1333 Sentence denotes The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI:
T13 1334-1359 Sentence denotes 0.47, 0.81; p<or=0.001)).
T14 1360-1615 Sentence denotes The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
T15 1616-1745 Sentence denotes Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
T16 1746-1758 Sentence denotes CONCLUSIONS:
T17 1759-1890 Sentence denotes Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.
T18 1891-2029 Sentence denotes Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.
T1 0-189 Sentence denotes Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
T2 190-200 Sentence denotes OBJECTIVE:
T3 201-377 Sentence denotes A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
T4 378-399 Sentence denotes PATIENTS AND METHODS:
T5 400-569 Sentence denotes A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
T6 570-634 Sentence denotes Use of gastroprotective agents and low-dose aspirin was allowed.
T7 635-791 Sentence denotes The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
T8 792-885 Sentence denotes General safety was also assessed, including adjudicated thrombotic cardiovascular event data.
T9 886-988 Sentence denotes Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
T10 989-997 Sentence denotes RESULTS:
T11 998-1144 Sentence denotes Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.
T12 1145-1333 Sentence denotes The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI:
T13 1334-1359 Sentence denotes 0.47, 0.81; p<or=0.001)).
T14 1360-1615 Sentence denotes The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
T15 1616-1745 Sentence denotes Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
T16 1746-1758 Sentence denotes CONCLUSIONS:
T17 1759-1890 Sentence denotes Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.
T18 1891-2029 Sentence denotes Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.

LitCoin-entities

Id Subject Object Predicate Lexical cue db_id
4491 33-43 ChemicalEntity denotes etoricoxib MESH:D000077613
4492 47-67 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis MESH:D001172
4493 68-76 OrganismTaxon denotes patients NCBITaxon:9606
4494 93-103 ChemicalEntity denotes etoricoxib MESH:D000077613
4495 107-124 ChemicalEntity denotes diclofenac sodium MESH:D004008
4496 308-318 ChemicalEntity denotes etoricoxib MESH:D000077613
4497 323-333 ChemicalEntity denotes diclofenac MESH:D004008
4498 337-345 OrganismTaxon denotes patients NCBITaxon:9606
4499 351-371 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis MESH:D001172
4500 373-375 DiseaseOrPhenotypicFeature denotes RA MESH:D001172
4501 378-386 OrganismTaxon denotes PATIENTS NCBITaxon:9606
4502 416-424 OrganismTaxon denotes patients NCBITaxon:9606
4503 462-464 DiseaseOrPhenotypicFeature denotes RA MESH:D001172
4504 492-502 ChemicalEntity denotes etoricoxib MESH:D000077613
4505 529-539 ChemicalEntity denotes diclofenac MESH:D004008
4506 614-621 ChemicalEntity denotes aspirin MESH:D001241
4507 706-713 OrganismTaxon denotes patient NCBITaxon:9606
4508 762-784 DiseaseOrPhenotypicFeature denotes GI adverse experiences MESH:D005767
4509 848-873 DiseaseOrPhenotypicFeature denotes thrombotic cardiovascular MESH:D002318
4510 919-926 OrganismTaxon denotes Patient NCBITaxon:9606
4511 1097-1107 ChemicalEntity denotes etoricoxib MESH:D000077613
4512 1112-1122 ChemicalEntity denotes diclofenac MESH:D004008
4513 1188-1194 DiseaseOrPhenotypicFeature denotes GI AEs MESH:D005767
4514 1224-1234 ChemicalEntity denotes etoricoxib MESH:D000077613
4515 1240-1250 ChemicalEntity denotes diclofenac MESH:D004008
4516 1278-1285 OrganismTaxon denotes patient NCBITaxon:9606
4517 1398-1410 DiseaseOrPhenotypicFeature denotes hypertension MESH:D006973
4518 1423-1429 DiseaseOrPhenotypicFeature denotes oedema MESH:D004487
4519 1473-1483 ChemicalEntity denotes etoricoxib MESH:D000077613
4520 1527-1537 ChemicalEntity denotes diclofenac MESH:D004008
4521 1579-1591 DiseaseOrPhenotypicFeature denotes hypertension MESH:D006973
4522 1607-1613 DiseaseOrPhenotypicFeature denotes oedema MESH:D004487
4523 1616-1626 ChemicalEntity denotes Etoricoxib MESH:D000077613
4524 1631-1641 ChemicalEntity denotes diclofenac MESH:D004008
4525 1759-1769 ChemicalEntity denotes Etoricoxib MESH:D000077613
4526 1851-1857 DiseaseOrPhenotypicFeature denotes GI AEs MESH:D005767
4527 1872-1882 ChemicalEntity denotes diclofenac MESH:D004008
4528 1979-1985 DiseaseOrPhenotypicFeature denotes GI AEs MESH:D005767
4529 2018-2028 ChemicalEntity denotes etoricoxib MESH:D000077613

LitCoin-sentences

Id Subject Object Predicate Lexical cue
T1 0-189 Sentence denotes Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
T2 190-200 Sentence denotes OBJECTIVE:
T3 201-377 Sentence denotes A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
T4 378-399 Sentence denotes PATIENTS AND METHODS:
T5 400-569 Sentence denotes A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
T6 570-634 Sentence denotes Use of gastroprotective agents and low-dose aspirin was allowed.
T7 635-791 Sentence denotes The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
T8 792-885 Sentence denotes General safety was also assessed, including adjudicated thrombotic cardiovascular event data.
T9 886-988 Sentence denotes Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
T10 989-997 Sentence denotes RESULTS:
T11 998-1144 Sentence denotes Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.
T12 1145-1333 Sentence denotes The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI:
T13 1334-1359 Sentence denotes 0.47, 0.81; p<or=0.001)).
T14 1360-1615 Sentence denotes The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
T15 1616-1745 Sentence denotes Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
T16 1746-1758 Sentence denotes CONCLUSIONS:
T17 1759-1890 Sentence denotes Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.
T18 1891-2029 Sentence denotes Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.

LitCoin_Mondo

Id Subject Object Predicate Lexical cue mondo_id
T1 47-67 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis 0008383
T2 351-371 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis 0008383

LitCoin-GeneOrGeneProduct-v0

Id Subject Object Predicate Lexical cue
T1 17-29 GeneOrGeneProduct denotes tolerability
T2 142-154 GeneOrGeneProduct denotes tolerability
T3 185-187 GeneOrGeneProduct denotes II
T4 215-221 GeneOrGeneProduct denotes double
T5 222-227 GeneOrGeneProduct denotes blind
T6 267-269 GeneOrGeneProduct denotes GI
T7 271-283 GeneOrGeneProduct denotes tolerability
T8 387-398 GeneOrGeneProduct denotes AND METHODS
T9 402-407 GeneOrGeneProduct denotes total
T10 440-445 GeneOrGeneProduct denotes years
T11 506-508 GeneOrGeneProduct denotes mg
T12 543-545 GeneOrGeneProduct denotes mg
T13 660-663 GeneOrGeneProduct denotes end
T14 664-669 GeneOrGeneProduct denotes point
T15 762-764 GeneOrGeneProduct denotes GI
T16 964-969 GeneOrGeneProduct denotes PGADS
T17 975-980 GeneOrGeneProduct denotes point
T18 1188-1190 GeneOrGeneProduct denotes GI
T19 1270-1273 GeneOrGeneProduct denotes per
T20 1286-1291 GeneOrGeneProduct denotes years
T21 1398-1410 GeneOrGeneProduct denotes hypertension
T22 1485-1488 GeneOrGeneProduct denotes 2.5
T23 1579-1591 GeneOrGeneProduct denotes hypertension
T24 1664-1671 GeneOrGeneProduct denotes similar
T25 1682-1687 GeneOrGeneProduct denotes PGADS
T26 1773-1775 GeneOrGeneProduct denotes mg
T27 1851-1853 GeneOrGeneProduct denotes GI
T28 1887-1889 GeneOrGeneProduct denotes mg
T29 1979-1981 GeneOrGeneProduct denotes GI

LitCoin-GeneOrGeneProduct-v2

Id Subject Object Predicate Lexical cue
T1 215-221 GeneOrGeneProduct denotes double
T2 222-227 GeneOrGeneProduct denotes blind
T3 1398-1410 GeneOrGeneProduct denotes hypertension
T4 1579-1591 GeneOrGeneProduct denotes hypertension
T5 1664-1671 GeneOrGeneProduct denotes similar

LitCoin-Disease-MeSH

Id Subject Object Predicate Lexical cue originalLabel
T1 47-67 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T2 351-371 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T3 373-375 DiseaseOrPhenotypicFeature denotes RA D001172
T4 462-464 DiseaseOrPhenotypicFeature denotes RA D001172
T5 948-955 DiseaseOrPhenotypicFeature denotes Disease D004194
T6 1398-1410 DiseaseOrPhenotypicFeature denotes hypertension D006973
T7 1579-1591 DiseaseOrPhenotypicFeature denotes hypertension D006973

LitCoin_Mondo_095

Id Subject Object Predicate Lexical cue mondo_id
T1 47-67 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis 0008383
T2 351-371 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis 0008383
T3 373-375 DiseaseOrPhenotypicFeature denotes RA 0008383|0005272
T5 462-464 DiseaseOrPhenotypicFeature denotes RA 0008383|0005272
T7 1004-1006 DiseaseOrPhenotypicFeature denotes SD 0011449
T8 1398-1410 DiseaseOrPhenotypicFeature denotes hypertension 0005044
T9 1579-1591 DiseaseOrPhenotypicFeature denotes hypertension 0005044

LitCoin-MeSH-Disease-2

Id Subject Object Predicate Lexical cue ID:
T1 47-67 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T2 351-371 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T3 373-375 DiseaseOrPhenotypicFeature denotes RA D001172
T4 462-464 DiseaseOrPhenotypicFeature denotes RA D001172
T5 762-784 DiseaseOrPhenotypicFeature denotes GI adverse experiences DISEASE
T6 848-873 DiseaseOrPhenotypicFeature denotes thrombotic cardiovascular DISEASE
T7 948-955 DiseaseOrPhenotypicFeature denotes Disease D004194
T8 1188-1194 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE
T9 1398-1410 DiseaseOrPhenotypicFeature denotes hypertension D006973
T10 1423-1429 DiseaseOrPhenotypicFeature denotes oedema DISEASE
T11 1579-1591 DiseaseOrPhenotypicFeature denotes hypertension D006973
T12 1607-1613 DiseaseOrPhenotypicFeature denotes oedema DISEASE
T13 1851-1857 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE
T14 1979-1985 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE

LitCoin-MONDO_bioort2019

Id Subject Object Predicate Lexical cue #label
T1 47-67 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T2 351-371 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T3 373-375 DiseaseOrPhenotypicFeature denotes RA D001172
T4 462-464 DiseaseOrPhenotypicFeature denotes RA D001172
T5 762-784 DiseaseOrPhenotypicFeature denotes GI adverse experiences DISEASE
T6 848-873 DiseaseOrPhenotypicFeature denotes thrombotic cardiovascular DISEASE
T7 1188-1194 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE
T8 1398-1410 DiseaseOrPhenotypicFeature denotes hypertension D006973
T9 1423-1429 DiseaseOrPhenotypicFeature denotes oedema DISEASE
T10 1579-1591 DiseaseOrPhenotypicFeature denotes hypertension D006973
T11 1607-1613 DiseaseOrPhenotypicFeature denotes oedema DISEASE
T12 1851-1857 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE
T13 1979-1985 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE

LitCoin-NCBITaxon-2

Id Subject Object Predicate Lexical cue
T1 68-76 OrganismTaxon denotes patients
T2 337-345 OrganismTaxon denotes patients
T3 416-424 OrganismTaxon denotes patients
T4 706-713 OrganismTaxon denotes patient
T5 919-926 OrganismTaxon denotes Patient
T6 1278-1285 OrganismTaxon denotes patient

LitCoin-Chemical-MeSH-CHEBI

Id Subject Object Predicate Lexical cue ID:
T1 33-43 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339
T3 93-103 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339
T5 107-124 ChemicalEntity denotes diclofenac sodium D004008|http://purl.obolibrary.org/obo/CHEBI_4509
T7 308-318 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339
T9 323-333 ChemicalEntity denotes diclofenac D004008|http://purl.obolibrary.org/obo/CHEBI_47381
T11 492-502 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339
T13 529-539 ChemicalEntity denotes diclofenac D004008|http://purl.obolibrary.org/obo/CHEBI_47381
T15 614-621 ChemicalEntity denotes aspirin D001241
T16 1097-1107 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339
T18 1112-1122 ChemicalEntity denotes diclofenac D004008|http://purl.obolibrary.org/obo/CHEBI_47381
T20 1224-1234 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339
T22 1240-1250 ChemicalEntity denotes diclofenac D004008|http://purl.obolibrary.org/obo/CHEBI_47381
T24 1473-1483 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339
T26 1527-1537 ChemicalEntity denotes diclofenac D004008|http://purl.obolibrary.org/obo/CHEBI_47381
T28 1616-1626 ChemicalEntity denotes Etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339
T29 1631-1641 ChemicalEntity denotes diclofenac D004008|http://purl.obolibrary.org/obo/CHEBI_47381
T31 1759-1769 ChemicalEntity denotes Etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339
T32 1872-1882 ChemicalEntity denotes diclofenac D004008|http://purl.obolibrary.org/obo/CHEBI_47381
T34 2018-2028 ChemicalEntity denotes etoricoxib D000077613|http://purl.obolibrary.org/obo/CHEBI_6339

LitCoin-training-merged

Id Subject Object Predicate Lexical cue #label ID:
T34 2018-2028 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T32 1872-1882 ChemicalEntity denotes diclofenac http://purl.obolibrary.org/obo/CHEBI_47381|D004008
T31 1759-1769 ChemicalEntity denotes Etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339
T29 1631-1641 ChemicalEntity denotes diclofenac http://purl.obolibrary.org/obo/CHEBI_47381|D004008
T28 1616-1626 ChemicalEntity denotes Etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339
T26 1527-1537 ChemicalEntity denotes diclofenac http://purl.obolibrary.org/obo/CHEBI_47381|D004008
T24 1473-1483 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T22 1240-1250 ChemicalEntity denotes diclofenac http://purl.obolibrary.org/obo/CHEBI_47381|D004008
T20 1224-1234 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T18 1112-1122 ChemicalEntity denotes diclofenac http://purl.obolibrary.org/obo/CHEBI_47381|D004008
T16 1097-1107 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T15 614-621 ChemicalEntity denotes aspirin D001241
T13 529-539 ChemicalEntity denotes diclofenac http://purl.obolibrary.org/obo/CHEBI_47381|D004008
T11 492-502 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T9 323-333 ChemicalEntity denotes diclofenac http://purl.obolibrary.org/obo/CHEBI_47381|D004008
T7 308-318 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T5 107-124 ChemicalEntity denotes diclofenac sodium http://purl.obolibrary.org/obo/CHEBI_4509|D004008
T3 93-103 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T1 33-43 ChemicalEntity denotes etoricoxib http://purl.obolibrary.org/obo/CHEBI_6339|D000077613
T20582 1979-1985 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE
T12 1851-1857 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE
T76797 1607-1613 DiseaseOrPhenotypicFeature denotes oedema DISEASE
T10 1579-1591 DiseaseOrPhenotypicFeature denotes hypertension D006973
T72806 1423-1429 DiseaseOrPhenotypicFeature denotes oedema DISEASE
T8 1398-1410 DiseaseOrPhenotypicFeature denotes hypertension D006973
T4114 1188-1194 DiseaseOrPhenotypicFeature denotes GI AEs DISEASE
T6 848-873 DiseaseOrPhenotypicFeature denotes thrombotic cardiovascular DISEASE
T80756 762-784 DiseaseOrPhenotypicFeature denotes GI adverse experiences DISEASE
T4 462-464 DiseaseOrPhenotypicFeature denotes RA D001172
T74145 373-375 DiseaseOrPhenotypicFeature denotes RA D001172
T2 351-371 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T13428 47-67 DiseaseOrPhenotypicFeature denotes rheumatoid arthritis D001172
T47220 1278-1285 OrganismTaxon denotes patient
T48864 919-926 OrganismTaxon denotes Patient
T1903 706-713 OrganismTaxon denotes patient
T54628 416-424 OrganismTaxon denotes patients
T69613 337-345 OrganismTaxon denotes patients
T68742 68-76 OrganismTaxon denotes patients

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 222-227 HP_0000618 denotes blind
T2 351-371 HP_0001370 denotes rheumatoid arthritis
T3 362-371 HP_0001369 denotes arthritis

bc5cdr-valid-experiment

Id Subject Object Predicate Lexical cue
T1 33-43 Chemical denotes etoricoxib
T2 47-67 Disease denotes rheumatoid arthritis
T3 93-103 Chemical denotes etoricoxib
T4 107-124 Chemical denotes diclofenac sodium
T5 308-318 Chemical denotes etoricoxib
T6 323-333 Chemical denotes diclofenac
T7 351-371 Disease denotes rheumatoid arthritis
T8 373-375 Disease denotes RA
T9 462-464 Disease denotes RA
T10 492-502 Chemical denotes etoricoxib
T11 529-539 Chemical denotes diclofenac
T12 614-621 Chemical denotes aspirin
T13 848-873 Disease denotes thrombotic cardiovascular
T14 1097-1107 Chemical denotes etoricoxib
T15 1112-1122 Chemical denotes diclofenac
T16 1188-1194 Disease denotes GI AEs
T17 1224-1234 Chemical denotes etoricoxib
T18 1240-1250 Chemical denotes diclofenac
T19 1398-1410 Disease denotes hypertension
T20 1423-1429 Disease denotes oedema
T21 1473-1483 Chemical denotes etoricoxib
T22 1527-1537 Chemical denotes diclofenac
T23 1579-1591 Disease denotes hypertension
T24 1607-1613 Disease denotes oedema
T25 1616-1626 Chemical denotes Etoricoxib
T26 1631-1641 Chemical denotes diclofenac
T27 1759-1769 Chemical denotes Etoricoxib
T28 1851-1857 Disease denotes GI AEs
T29 1872-1882 Chemical denotes diclofenac
T30 1979-1985 Disease denotes GI AEs
T31 2018-2028 Chemical denotes etoricoxib